Enzalutamide in Metastatic Prostate Cancer. Reply

Affiliations

¹ Monash University Eastern Health Clinical School, Melbourne, VIC, Australia ian.davis@monash.edu.
² University of Sydney National Health and Medical Research Council Clinical Trials Centre, Sydney, NSW, Australia.
³ Dana-Farber Cancer Institute, Boston, MA.

Comment

Ian D Davis et al. N Engl J Med. 2019.

. 2019 Oct 10;381(15):1494-1495.

doi: 10.1056/NEJMc1910553.

¹ Monash University Eastern Health Clinical School, Melbourne, VIC, Australia ian.davis@monash.edu.
² University of Sydney National Health and Medical Research Council Clinical Trials Centre, Sydney, NSW, Australia.
³ Dana-Farber Cancer Institute, Boston, MA.

No abstract available

Comment on

Enzalutamide in Metastatic Prostate Cancer.
Varkaris A, Bubley G. Varkaris A, et al. N Engl J Med. 2019 Oct 10;381(15):1493. doi: 10.1056/NEJMc1910553. N Engl J Med. 2019. PMID: 31597030 No abstract available.
Enzalutamide in Metastatic Prostate Cancer.
Yin M, Vinh-Hung V, Verschraegen C. Yin M, et al. N Engl J Med. 2019 Oct 10;381(15):1493-1494. doi: 10.1056/NEJMc1910553. N Engl J Med. 2019. PMID: 31597031 No abstract available.
Enzalutamide in Metastatic Prostate Cancer.
Levêque D. Levêque D. N Engl J Med. 2019 Oct 10;381(15):1494. doi: 10.1056/NEJMc1910553. N Engl J Med. 2019. PMID: 31597032 No abstract available.